BioCentury | Aug 1, 2018
Distillery Therapeutics


INDICATION: Autism Mouse studies suggest inhibiting MAPK could help treat autism. In a mouse model of autism, subcutaneous injection with a tool compound MAPK inhibitor decreased numbers of cortical progenitor cells and behavioral deficits and...
BioCentury | Oct 13, 2017
Emerging Company Profile

CBT’s silk road

While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop...
BioCentury | Jul 25, 2017
Distillery Therapeutics


INDICATION: Lung cancer; melanoma Mouse studies suggest combining Mekinist trametinib with MAPK and CRAF inhibitors could help treat BRAF -dependent lung cancer and melanoma. In six PDX mouse models of BRAF-dependent lung cancer and five...
Items per page:
1 - 3 of 3